Adverse drug-drug interactions (DDIs) pose potential risks in polypharmacy due to unknown physicochemical incompatibilities between co-administered drugs. Recent studies have utilized multi-layer graph neural network architectures to model hierarchical molecular substructures of drugs, achieving excellent DDI prediction performance. While extant substructural frameworks effectively encode interactions from atom-level features, they overlook valuable chemical bond representations within molecular graphs. More critically, given the multifaceted nature of DDI prediction tasks involving both known and novel drug combinations, previous methods lack tailored strategies to address these distinct scenarios. The resulting lack of adaptability impedes further improvements to model performance. To tackle these challenges, we propose PEB-DDI, a DDI prediction learning framework with enhanced substructure extraction. First, the information of chemical bonds is integrated and synchronously updated with the atomic nodes. Then, different dual-view strategies are selected based on whether novel drugs are present in the prediction task. Particularly, we constructed Molecular fingerprint-Molecular graph view for transductive task, and Bipartite graph-Molecular graph view for inductive task. Rigorous evaluations on benchmark datasets underscore PEB-DDI's superior performance. Notably, on DrugBank, it achieves an outstanding accuracy rate of 98.18% when predicting previously unknown interactions among approved drugs. Even when faced with novel drugs, PEB-DDI consistently exhibits outstanding generalization capabilities with an accuracy rate of 88.06%, attributing to the proper migrating of molecular basic structure learning.

Download full-text PDF

Source
http://dx.doi.org/10.1109/JBHI.2023.3335402DOI Listing

Publication Analysis

Top Keywords

ddi prediction
12
learning framework
8
novel drugs
8
graph view
8
accuracy rate
8
prediction
5
drugs
5
peb-ddi task-specific
4
task-specific dual-view
4
dual-view substructural
4

Similar Publications

Adsorption isotherms in roasted specialty coffee ( L.): Dataset and statistical tools for optimizing storage conditions and enhancing shelf life.

Data Brief

February 2025

Centro Surcolombiano de Investigación en Café (CESURCAFÉ), Departamento de Ingeniería Agrícola, Universidad Surcolombiana, Neiva-Huila 410001, Colombia.

This work presents a comprehensive dataset of adsorption isotherms and infrared spectral data for roasted specialty coffee ( L.). The dataset includes adsorption isotherms for whole roasted beans and ground coffee at medium (850 µm) and fine (600 µm) particle sizes.

View Article and Find Full Text PDF

Clinical Assessment of Drug Transporter Inhibition Using Biomarkers: Review of the Literature (2015-2024).

J Clin Pharmacol

January 2025

Drug Metabolism and Nonclinical Pharmacokinetics, Translational Medicine, Incyte, Wilmington, DE, USA.

As part of a narrative review of various publications describing the clinical use of urine- and plasma-based drug transporter biomarkers, it was determined that the utilization of coproporphyrin I, a hepatic organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 biomarker, has been reported for 28 different drug-drug interaction (DDI) perpetrator drugs. Similarly, biomarkers for liver organic cation transporter 1 (isobutyryl-l-carnitine, N = 7 inhibitors), renal organic cation transporter 2 and multidrug and toxin extrusion proteins (N-methylnicotinamide, N = 13 inhibitors), renal organic anion transporter (OAT) 1 and 3 (pyridoxic acid, N = 7 inhibitors), and breast cancer resistance protein (riboflavin, N = 3 inhibitors) have also been described. Increased use of biomarkers has also been accompanied by modeling efforts to enable DDI predictions and development of multiplexed methods to facilitate their bioanalysis.

View Article and Find Full Text PDF

Objective: To develop a nomogram to predict the risk of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients.

Methods: Patients diagnosed with HCC at Hunan Provincial People's Hospital between January 2010 and January 2022 were enrolled. Data on demographic characteristics, comorbidities, and laboratory tests were collected.

View Article and Find Full Text PDF

Background: In the medical context where polypharmacy is increasingly common, accurately predicting drug-drug interactions (DDIs) is necessary for enhancing clinical medication safety and personalized treatment. Despite progress in identifying potential DDIs, a deep understanding of the underlying mechanisms of DDIs remains limited, constraining the rapid development and clinical application of new drugs.

Methods: This study introduces a novel multimodal drug-drug interaction (MMDDI) model based on multi-source drug data and comprehensive feature fusion techniques, aiming to improve the accuracy and depth of DDI prediction.

View Article and Find Full Text PDF

Predicting Drug-Drug Interactions (DDIs) enables cost reduction and time savings in the drug discovery process, while effectively screening and optimizing drugs. The intensification of societal aging and the increase in life stress have led to a growing number of patients suffering from both heart disease and depression. These patients often need to use cardiovascular drugs and antidepressants for polypharmacy, but potential DDIs may compromise treatment effectiveness and patient safety.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!